- €14.09bn
- €14.09bn
- €1.89bn
Europe Research Roundup: Air France-KLM, Burberry, Wise
Jefferies hikes Orion to 'buy' on better Nubeqa sales forecast
Brief: Orion Provides Positive Data From Darolutamide Studies
Orion slips despite outlook hike, analyst points to likely profit taking
Brief: Orion Upgrades 2024 Outlook
Jefferies ups Orion on strong Nubeqa sales
Europe Research Roundup: Crest Nicholson Holdings, JDE Peet's, L'Oreal
Brief: Orion Expects Gross Profit To Increase, Mostly Driven By Growing Nubeqa Royalties
Brief: Orion Q2 Operating Profit EUR 65.8 Million Vs. Estimate EUR 58.3 Million
Earnings Poll: Orion Oyj second quarter results due on August 8
Bayer eyes wider Nubeqa use on new prostate cancer trial data (updated)
Bayer says darolutamide shown to slow prostate cancer progression
Brief: Orion Says Phase III Aranote Trial Of Darolutamide Meets Primary Endpoint
Brief: Orion Upgrades Full-Year Outlook For 2024
Brief: Orion To Provide MSD Global Exclusive Rights To Opevesostat
Brief: Orion Participates In Project Led By University Of Turku
FY EBIT outlook upgrade lifts Orion shares
Brief: Orion Says Strikes Did Not Have Material Impact In Q1
Brief: Orion Q1 Operating Profit EUR 56 Million Vs. Estimate EUR 57.3 Million